Hevascol

Hevascol is a radiographic contrast agent whose active ingredient is ethyl esters of iodised fatty acids derived from poppyseed oil. It is supplied as a sterile solution for injection, intended for intra‑arterial, intralymphatic or intra‑uterine administration. Marketed in the European Union and available by prescription, Hevascol provides iodine atoms that enhance X‑ray attenuation, facilitating clearer visualization of vascular and lymphatic structures during diagnostic imaging procedures.

Hevascol is employed in diagnostic radiology to improve image contrast for several specialized procedures.

- Angiography of arterial and venous systems, providing detailed vessel delineation. - Lymphography for mapping lymphatic channels and detecting metastatic spread. - Uterine imaging, including hysterosalpingography, to assess cavity patency. - Peripheral vascular studies in patients with renal impairment where low‑osmolality agents are preferred. - Interventional radiology guidance during catheter placement or embolization procedures. - Cerebral angiography to visualize intracranial arteries and detect aneurysms. - Peripheral limb perfusion studies in diabetic patients to evaluate microvascular disease.

Adverse reactions to Hevascol are generally related to its iodine content and the injection process.

Common: - Transient warmth or flushing sensation at the injection site. - Mild nausea or vomiting occurring shortly after administration. - Headache or dizziness lasting a few minutes. - Temporary metallic taste in the mouth. - Mild itching or erythema around the infusion site. - Temporary increase in serum creatinine that resolves within 48 hours.

Serious: - Acute hypersensitivity reactions, including urticaria, bronchospasm, or anaphylaxis. - Significant renal function decline in patients with pre‑existing kidney disease. - Severe hypotension or cardiovascular collapse. - Pulmonary edema or acute respiratory distress syndrome. - Cardiac arrhythmias, including ventricular tachycardia, triggered by contrast exposure. - Severe skin reactions such as Stevens‑Johnson syndrome.

Before using Hevascol, clinicians should evaluate patient history and clinical status to minimize risk of adverse events.

- Assess renal function; avoid or adjust use in patients with severe impairment. - Review history of iodine or contrast media allergy and consider pre‑medication if needed. - Use the lowest effective volume and concentration for the specific imaging study. - Monitor vital signs during and after injection, especially in high‑risk patients. - Exercise caution in pregnant or breastfeeding women due to unknown fetal exposure. - Avoid use in patients with uncontrolled hyperthyroidism because iodine load may exacerbate the condition.

Hevascol may interact with other agents that affect renal function, iodine metabolism, or allergic response.

Avoid: - Concurrent use of other high‑iodine contrast media during the same imaging session. - Administration with nephrotoxic drugs such as aminoglycosides or non‑steroidal anti‑inflammatory drugs (NSAIDs) in patients with compromised kidneys. - Use together with iodinated thyroid medications (e.g., amiodarone) in patients with hyperthyroidism.

Use with caution: - Co‑administration of beta‑blockers, which may mask early signs of anaphylactoid reactions. - Concurrent diuretics; monitor fluid balance to prevent dehydration. - Patients receiving anticoagulants; observe for potential bleeding at the injection site.